Employer coverage decides whether a great many people pay cash, which makes it a pricing question as much as a benefits one. A survey collected baseline responses from 518 full-time employed adults starting tirzepatide for obesity or overweight (n = 518, mean age 46.0 years, mean BMI 38.4) [1]. It sits directly against the employer-side figure in 19 percent of large firms cover it.
That juxtaposition is the most useful thing here. Among respondents with employer insurance, 55.9% reported coverage for obesity medications — far above the share of large employers offering it. Both figures can be accurate at once, because this sample consists entirely of people who managed to start the drug, and having coverage is one of the main reasons someone manages that. The survey is describing the winners of a filter, not the population.
The number worth an employer's attention is the retention one. A little over half, 52.3%, said they would consider changing jobs to obtain coverage for obesity medication, and 81.7% said such coverage could increase job satisfaction. Whether stated intentions survive contact with an actual job offer is another matter, but a benefit that half a workforce segment would move for is priced differently from one nobody notices.
For a reader paying cash, the practical reading is that coverage is worth asking about directly rather than assumed absent, since more than half of these insured respondents had it. Human resources departments and plan documents are where that is settled, and formulary rules change more often than people check. What coverage does to the price is in what insurance coverage costs, and why so many people who qualify still go untreated is in covered and still not treated.
The work productivity measure, assessed with a standard impairment questionnaire, is the thread an employer would actually pull on, since it converts a benefit cost into an operational one. This is baseline data from a longitudinal study, so the follow-up will be the more informative half — whether the impairment scores move is the question, and it has not been answered yet. Self-reported experience from people on these drugs is worth reading beside it, and is collected in what patients said when asked.